{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:06:54Z","timestamp":1790737614611,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondazione Italiana per la Ricerca sulla Fibrosi Cistica (Project FFC 8\/2019)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>In recent years, we have discovered Esc(1-21) and its diastereomer (Esc peptides) as valuable candidates for the treatment of Pseudomonas lung infection, especially in patients with cystic fibrosis (CF). Furthermore, engineered poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) were revealed to be a promising pulmonary delivery system of antimicrobial peptides. However, the \u201cad hoc\u201d development of novel therapeutics requires consideration of their stability, tolerability, and safety. Hence, by means of electrophysiology experiments and preclinical studies on healthy mice, we demonstrated that neither Esc peptides or Esc-peptide-loaded PLGA NPs significantly affect the integrity of the lung epithelium, nor change the global gene expression profile of lungs of treated animals compared to those of vehicle-treated animals. Noteworthy, the Esc diastereomer endowed with the highest antimicrobial activity did not provoke any pulmonary pro-inflammatory response, even at a concentration 15-fold higher than the efficacy dosage 24 h after administration in the free or encapsulated form. The therapeutic index was \u226570, and the peptide was found to remain available in the bronchoalveolar lavage of mice, after two days of incubation. Overall, these studies should open an avenue for a new up-and-coming pharmacological approach, likely based on inhalable peptide-loaded NPs, to address CF lung disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics14112297","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:17:48Z","timestamp":1666768668000},"page":"2297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pulmonary Safety Profile of Esc Peptides and Esc-Peptide-Loaded Poly(lactide-co-glycolide) Nanoparticles: A Promising Therapeutic Approach for Local Treatment of Lung Infectious Diseases"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-8474","authenticated-orcid":false,"given":"Floriana","family":"Cappiello","sequence":"first","affiliation":[{"name":"Department of Biochemical Sciences, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-1084","authenticated-orcid":false,"given":"Bruno","family":"Casciaro","sequence":"additional","affiliation":[{"name":"Department of Biochemical Sciences, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Loffredo","sequence":"additional","affiliation":[{"name":"Department of Biochemical Sciences, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Biochemical Sciences, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7017-8483","authenticated-orcid":false,"given":"Qiao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15261, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15261, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-1519","authenticated-orcid":false,"given":"Gemma","family":"Conte","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0444-0444","authenticated-orcid":false,"given":"Ivana","family":"d\u2019Angelo","sequence":"additional","affiliation":[{"name":"Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania Luigi Vanvitelli, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-9533","authenticated-orcid":false,"given":"Francesca","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Ferrera","sequence":"additional","affiliation":[{"name":"U.O.C. Genetica Medica, IRCCS, Istituto Giannina Gaslini, 16147 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Biophysic Institute, Consiglio Nazionale delle Ricerche (CNR), 16149 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cresti","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pini","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-2087","authenticated-orcid":false,"given":"Yuanpu Peter","family":"Di","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15261, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-5868","authenticated-orcid":false,"given":"Maria Luisa","family":"Mangoni","sequence":"additional","affiliation":[{"name":"Department of Biochemical Sciences, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-019-0662-8","article-title":"European intensive care physicians\u2019 experience of infections due to antibiotic-resistant bacteria","volume":"9","author":"Lepape","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fpubh.2020.00026","article-title":"Essential Metabolic Routes as a Way to ESKAPE From Antibiotic Resistance","volume":"8","author":"Barra","year":"2020","journal-title":"Front. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Browne, K., Chakraborty, S., Chen, R., Willcox, M.D., Black, D.S., Walsh, W.R., and Kumar, N. (2020). A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197047"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","article-title":"Antimicrobial Peptides: An Emerging Category of Therapeutic Agents","volume":"6","author":"Mahlapuu","year":"2016","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","article-title":"Antimicrobial host defence peptides: Functions and clinical potential","volume":"19","author":"Mookherjee","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/07388551.2020.1796576","article-title":"Antimicrobial peptides as therapeutic agents: Opportunities and challenges","volume":"40","author":"Mahlapuu","year":"2020","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e24122","DOI":"10.1002\/pep2.24122","article-title":"Antimicrobial peptides under clinical investigation","volume":"111","author":"Koo","year":"2019","journal-title":"Pept. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"616979","DOI":"10.3389\/fmicb.2021.616979","article-title":"Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)","volume":"12","author":"Dijksteel","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.iy.13.040195.000425","article-title":"Peptide antibiotics and their role in innate immunity","volume":"13","author":"Boman","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s00018-005-5536-y","article-title":"Temporins, anti-infective peptides with expanding properties","volume":"63","author":"Mangoni","year":"2006","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00018-013-1291-7","article-title":"Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa","volume":"70","author":"Luca","year":"2013","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4187\/aarc0443","article-title":"Pulmonary complications of cystic fibrosis","volume":"54","author":"Flume","year":"2009","journal-title":"Respir. Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","article-title":"Structure and function of the CFTR chloride channel","volume":"79","author":"Sheppard","year":"1999","journal-title":"Physiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(91)90446-6","article-title":"Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel","volume":"66","author":"Cheng","year":"1991","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biocel.2014.03.020","article-title":"Biosynthesis of cystic fibrosis transmembrane conductance regulator","volume":"52","author":"Pranke","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s00726-015-2041-y","article-title":"D-Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1-21)NH2 is beneficial for its multiple functions","volume":"47","author":"Cappiello","year":"2015","journal-title":"Amino Acids"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1128\/AAC.00904-16","article-title":"Esculentin-1a-Derived Peptides Promote Clearance of Pseudomonas aeruginosa Internalized in Bronchial Cells of Cystic Fibrosis Patients and Lung Cell Migration: Biochemical Properties and a Plausible Mode of Action","volume":"60","author":"Cappiello","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"18988","DOI":"10.1038\/s41598-019-55426-x","article-title":"Bronchial epithelium repair by Esculentin-1a-derived antimicrobial peptides: Involvement of metalloproteinase-9 and interleukin-8, and evaluation of peptides\u2019 immunogenicity","volume":"9","author":"Cappiello","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jcf.2018.03.010","article-title":"CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts","volume":"17","author":"Adam","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00018-021-04030-2","article-title":"Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: An unprecedented property of antimicrobial peptides","volume":"79","author":"Ferrera","year":"2021","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1038\/s41598-017-08361-8","article-title":"In vivo therapeutic efficacy of frog skin-derived peptides against Pseudomonas aeruginosa-induced pulmonary infection","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1021\/acs.biomac.8b01829","article-title":"Poly(lactide- co-glycolide) Nanoparticles for Prolonged Therapeutic Efficacy of Esculentin-1a-Derived Antimicrobial Peptides against Pseudomonas aeruginosa Lung Infection: In Vitro and in Vivo Studies","volume":"20","author":"Casciaro","year":"2019","journal-title":"Biomacromolecules"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","article-title":"Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling","volume":"301","author":"Sondo","year":"2011","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chembiol.2018.04.010","article-title":"Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia","volume":"25","author":"Sondo","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-0716-0223-2_5","article-title":"Using Bronchoalveolar Lavage to Evaluate Changes in Pulmonary Diseases","volume":"2102","author":"Di","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_32","first-page":"e55398","article-title":"Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration","volume":"123","author":"Job","year":"2017","journal-title":"J. Vis. Exp. JoVE"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eaay6817","DOI":"10.1126\/sciadv.aay6817","article-title":"Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria","volume":"6","author":"Di","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri.2016.29","article-title":"The immunology of host defence peptides: Beyond antimicrobial activity","volume":"16","author":"Hancock","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1208\/s12248-021-00611-y","article-title":"FDA\u2019s Poly (Lactic-Co-Glycolic Acid) Research Program and Regulatory Outcomes","volume":"23","author":"Wang","year":"2021","journal-title":"AAPS J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejpb.2018.07.025","article-title":"Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions","volume":"131","author":"Ernst","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40005-019-00456-w","article-title":"Poly(lactic acid)\/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery","volume":"49","author":"Emami","year":"2019","journal-title":"J. Pharm. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425247.5.6.629","article-title":"Biodegradable polymeric nanocarriers for pulmonary drug delivery","volume":"5","author":"Rytting","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102291","DOI":"10.1016\/j.nano.2020.102291","article-title":"The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats","volume":"30","author":"Haque","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.08.016","article-title":"PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing","volume":"194","author":"Chereddy","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"122002","DOI":"10.1088\/2053-1591\/ac3f5e","article-title":"PLGA-based drug delivery system for combined therapy of cancer: Research progress","volume":"8","author":"Zhang","year":"2021","journal-title":"Mater. Res. Express"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/acs.molpharmaceut.0c00692","article-title":"Exploring the Toxicity, Lung Distribution, and Cellular Uptake of Rifampicin and Ascorbic Acid-Loaded Alginate Nanoparticles as Therapeutic Treatment of Lung Intracellular Infections","volume":"18","author":"Scolari","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_44","first-page":"4713","article-title":"Crucial Role of PLGA Nanoparticles in Mitigating the Amiodarone-Induced Pulmonary Toxicity","volume":"16","author":"Motawea","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.2147\/DDDT.S275123","article-title":"Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells","volume":"14","author":"Shen","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/bm201226x","article-title":"Biodegradable nanoparticles meet the bronchial airway barrier: How surface properties affect their interaction with mucus and epithelial cells","volume":"12","author":"Mura","year":"2011","journal-title":"Biomacromolecules"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.nano.2016.03.002","article-title":"Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges","volume":"12","author":"Haque","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2011.12.004","article-title":"Controlled pulmonary drug and gene delivery using polymeric nano-carriers","volume":"161","author":"Merkel","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fchem.2017.00040","article-title":"D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection","volume":"5","author":"Mardirossian","year":"2017","journal-title":"Front. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00726-016-2266-4","article-title":"In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections","volume":"48","author":"Mardirossian","year":"2016","journal-title":"Amino Acids"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.45.12.3437-3444.2001","article-title":"P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients","volume":"45","author":"Sajjan","year":"2001","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/11\/2297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:03:10Z","timestamp":1760144590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/11\/2297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["pharmaceutics14112297"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14112297","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]}}}